Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 6 January 2026 - 8 January 2026

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward a pivotal, late-stage study. For small drug developers without a marketed product, one clinical readout can reset expectations fast. Pancreatic cancer is a tough proving ground. Survival gains are hard to show, and investors tend to discount early-stage results until
8 January 2026
···
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s next growth bets can outrun erosion in older blockbusters. The FDA on Tuesday approved Amneal’s denosumab biosimilars — near-copies of complex biologic drugs that typically enter at lower prices — as alternatives to Amgen’s Prolia and Xgeva, products with about
8 January 2026
···
Thermo Fisher stock slips after-hours as TD Cowen lifts target ahead of JPM talk, earnings

Thermo Fisher stock slips after-hours as TD Cowen lifts target ahead of JPM talk, earnings

New York, Jan 7, 2026, 18:54 EST — After-hours Thermo Fisher Scientific shares slipped about 0.6% in after-hours trading on Wednesday to $617.15, after swinging between $611.93 and $626.40 during the session. The dip comes with the stock sitting near recent highs and the calendar tightening. Investors are staring at next week’s J.P. Morgan Healthcare Conference and Thermo Fisher’s quarterly results later this month, looking for a clean read on demand and the 2026 setup. On Tuesday, the company said it enrolled the first patient in a new PPD CorEvitas obesity registry, a prospective study meant to collect “real-world evidence”
8 January 2026
···
Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

New York, January 7, 2026, 13:26 EST — Regular session Viasat shares fell $4.89, or about 11.3%, to $38.57 on Wednesday, a day after the stock closed at $43.46. The shares traded between $38.27 and $43.58. The drop comes as investors weigh whether Viasat’s Inmarsat business can keep landing big mobility customers that buy recurring service, not just hardware. Maritime contracts matter because they can be sticky, with ships typically locked into connectivity providers for years. That is a key question for Viasat heading into its next results, as the company tries to show steady demand across its mobility products
7 January 2026
····
Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity candidates aimed at INHBE or its receptor, ALK7. Arrowhead said its ARO-INHBE nearly doubled weight loss when paired with Eli Lilly’s tirzepatide, and drove what an outside expert called “dramatic and rapid reductions in visceral fat,” the fat that builds
7 January 2026
···
Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

New York, January 7, 2026, 12:25 (EST) — Regular session Shares of Adaptive Biotechnologies rose 6.5% to $17.15 on Wednesday, after trading between $16.24 and $17.33, giving the company a market value of about $2.0 billion. The stock has traded between $4.32 and $21.89 over the past 52 weeks. The move matters now because investors have been bidding up riskier biotech names again, and ADPT tends to swing with that tone. The SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF were each up about 2.5% in midday trade. The broader market was also higher, but not by as
7 January 2026
··
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

New York, Jan 7, 2026, 11:50 a.m. EST — Regular session Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort. The agreement matters because it puts near-term cash on the table for a clinical-stage biotech and suggests its intellectual property has value beyond its own pipeline, at a moment when markets are quick to price any edge in the crowded GLP-1 weight-loss race. A Form 8-K filing showed the company’s Gasherbrum Bio
7 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

New York, January 7, 2026, 09:54 EST — Regular session Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS. UBS began coverage of Pfizer with a Neutral rating and a $25 price target, pointing to what it described as revenue uncertainty as several big drugs face patent expirations in coming years. UBS estimated roughly $15 billion to $20 billion of annual revenue is exposed to loss of exclusivity — when patents expire and cheaper rivals move in —
7 January 2026
····
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

New York, Jan 6, 2026, 12:38 (EST) — Regular session Regencell Bioscience Holdings Ltd shares rose 18.3% to $31.99 on Tuesday, after touching $34.40 earlier and sliding as low as $26.60. The Nasdaq-listed stock was last up $4.95 from Monday’s close of $27.04, with about 850,000 shares traded. The move keeps the Hong Kong-based bioscience company on momentum traders’ radar at the start of 2026, after a run of outsized daily swings. In small, lightly followed stocks, rapid price shifts can draw more short-term flow — and just as quickly reverse when liquidity thins. Regencell’s investor-relations site has not posted
6 January 2026
··
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

New York, January 6, 2026, 11:28 EST — Regular session Wave Life Sciences Ltd shares (WVE.O) jumped about 17% on Tuesday, extending sharp swings in the obesity drug trade as investors sized up the next set of clinical readouts. The stock was up 17.2% at $17.58 in morning trade on Nasdaq, after moving between $14.15 and $19.49, with about 7.0 million shares traded. The move shows how quickly sentiment can shift in obesity-linked biotechs, where small early-stage updates often drive outsized price action. Investors are hunting for approaches that can cut harmful fat while preserving muscle, a sticking point for
6 January 2026
··
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com The update lands amid a scramble for new obesity treatments that can add to GLP-1 drugs — a fast-growing market where investors now weigh not just pounds lost, but what kind of weight comes off. Many patients and doctors want therapies that
6 January 2026
···
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

NEW YORK, Jan 6, 2026, 08:19 EST — Premarket Cyclerion Therapeutics Inc shares jumped about 46% to around $2.01 in premarket trading on Tuesday after the company announced an expanded strategic collaboration with Medsteer to advance its closed-loop anesthetic platform, CYC-126. Benzinga The move matters because Cyclerion is trying to pair an anesthetic-based approach with a device-and-software system that adjusts dosing using real-time feedback — a setup that can add complexity but also sharpen execution in early trials. For small biotechs, clearer milestones can quickly reset expectations for funding and timelines. Cyclerion said the agreement is exclusive and includes an
6 January 2026
··
1 … 5 6 7 8 9 … 25

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

7 February 2026
IREN shares closed up 5.1% at $41.83 Friday after reporting a $155.4 million quarterly loss and $184.7 million in revenue. The company announced $3.6 billion in GPU financing for its Microsoft contract, with $2.8 billion in cash as of Jan. 31. Bitcoin mining revenue fell, while AI cloud services rose. Traders await bitcoin’s weekend move and Monday’s market reaction.
Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

7 February 2026
Cadence Bank shares have been delisted following Huntington Bancshares’ takeover, with each Cadence share converted into 2.475 Huntington shares. Huntington closed Friday at $19.27 and named Senthil Kumar as chief risk officer ahead of new regulatory requirements. The merger leaves Cadence as a brand under Huntington, with customer account conversions planned for mid-2026. Huntington executives will address investors at a UBS conference on Tuesday.
Go toTop